Tag - Alzheimer’s disease

Feature

Strong scientific rationale for IntelGenx montelukast program

By Len Zehrs IntelGenx (OTCQX:IGXT; TSXV:IGX), which has initiated a proof-of-concept study with its Montelukast VersaFilm in patients with Alzheimer’s disease, using a drug originally approved in 1997 for the...

February 13, 2018

Feature

3D Signatures seeking partners for genomic imaging platform

By Len Zehr 3D Signatures (TSX-V:DXD) which has developed proprietary software with the potential to analyze a patient’s chromosomal arrangement, or signature, is seeking collaborations to advance its TeloView platform...

November 29, 2016

Feature

Anavex readies trial of AZ combo drug

By Len Zehr Anavex Life Sciences (OTCQB:AVXL) plans to begin a Phase 1b/2a clinical trial in the first quarter of 2014 of a novel combination drug candidate for the treatment of Alzheimer’s disease (AD). “In preclinical...

December 17, 2013

Tag - Alzheimer’s disease

Strong scientific rationale for IntelGenx montelukast program

3D Signatures seeking partners for genomic imaging platform

Anavex readies trial of AZ combo drug

General

More